CN101855218A - 氘化的儿茶酚和苯并[d][1,3]间二氧杂环戊烯及其衍生物的合成 - Google Patents

氘化的儿茶酚和苯并[d][1,3]间二氧杂环戊烯及其衍生物的合成 Download PDF

Info

Publication number
CN101855218A
CN101855218A CN200880110558A CN200880110558A CN101855218A CN 101855218 A CN101855218 A CN 101855218A CN 200880110558 A CN200880110558 A CN 200880110558A CN 200880110558 A CN200880110558 A CN 200880110558A CN 101855218 A CN101855218 A CN 101855218A
Authority
CN
China
Prior art keywords
coor
deuterated
represented
nhc
nhr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880110558A
Other languages
English (en)
Chinese (zh)
Inventor
A·D·琼斯
R·E·泽尔
I·R·西尔弗曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concert Pharmaceuticals Inc
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of CN101855218A publication Critical patent/CN101855218A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
CN200880110558A 2007-09-13 2008-09-12 氘化的儿茶酚和苯并[d][1,3]间二氧杂环戊烯及其衍生物的合成 Pending CN101855218A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99356507P 2007-09-13 2007-09-13
US60/993,565 2007-09-13
PCT/US2008/010643 WO2009035652A1 (en) 2007-09-13 2008-09-12 Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof

Publications (1)

Publication Number Publication Date
CN101855218A true CN101855218A (zh) 2010-10-06

Family

ID=40116877

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880110558A Pending CN101855218A (zh) 2007-09-13 2008-09-12 氘化的儿茶酚和苯并[d][1,3]间二氧杂环戊烯及其衍生物的合成

Country Status (8)

Country Link
US (2) US8822498B2 (enExample)
EP (2) EP2727915B1 (enExample)
JP (1) JP5647519B2 (enExample)
CN (1) CN101855218A (enExample)
AU (1) AU2008299921B2 (enExample)
CA (1) CA2698808A1 (enExample)
MX (1) MX2010002692A (enExample)
WO (1) WO2009035652A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102924426A (zh) * 2012-11-14 2013-02-13 广西师范大学 胡椒乙胺缩5-氯水杨醛及其合成方法和应用
CN102942554A (zh) * 2012-11-14 2013-02-27 广西师范大学 胡椒乙胺缩水杨醛及其合成方法和应用
CN103980271A (zh) * 2014-05-30 2014-08-13 天津长森药业有限公司 黄藤素及其类似物的制备方法
CN104059030A (zh) * 2014-05-30 2014-09-24 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
CN110179792A (zh) * 2014-07-29 2019-08-30 深圳君圣泰生物技术有限公司 小檗碱盐、熊去氧胆酸盐、相关复方及其制备方法和应用
CN113735847A (zh) * 2021-09-10 2021-12-03 四川大学 一种盐酸小檗碱的合成制备方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5301991B2 (ja) * 2005-07-29 2013-09-25 コンサート ファーマシューティカルズ インコーポレイテッド 新規なベンゾ［ｄ］［１，３］−ジオキソール誘導体
EP1948646A2 (en) * 2005-11-14 2008-07-30 Auspex Pharmaceuticals Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
AU2008299921B2 (en) 2007-09-13 2012-03-01 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
ME03652B (me) * 2011-05-18 2020-07-20 Vertex Pharmaceuticals Europe Ltd Deuterisani derivati ivakaftora
US20120302526A1 (en) * 2011-05-27 2012-11-29 Regents Of The University Of Colorado, A Body Corporate Methods for treating post-traumatic stress disorder
RU2696492C2 (ru) 2014-05-13 2019-08-02 Ф. Хоффманн-Ля Рош Аг Дейтрированные гетероциклические соединения и их применение в качестве средств визуализации
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
WO2017053711A2 (en) 2015-09-25 2017-03-30 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
CN108602786B (zh) 2016-02-25 2019-04-23 深圳市塔吉瑞生物医药有限公司 一种取代的噁二唑类化合物及包含该化合物的组合物及其用途
KR101970326B1 (ko) * 2016-08-05 2019-04-18 고려대학교 산학협력단 당 부가된 엔클로미펜, 이의 제조방법 및 이를 포함하는 약학적 조성물
CN111479804B (zh) 2017-12-01 2023-12-22 弗特克斯药品有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
WO1989001342A2 (en) * 1987-08-07 1989-02-23 Mallinckrodt, Inc. Diagnostic or radiotherapeutic composition comprising a hydrogen containing compound
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5708035A (en) 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
JP3696884B2 (ja) 1994-03-25 2005-09-21 アイソテクニカ、インコーポレーテッド ジュウテリウム化による薬物の効能の増強
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
GB9514842D0 (en) 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
US5958429A (en) 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
UA56185C2 (uk) 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US5776969A (en) 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
JP2001523245A (ja) 1997-04-24 2001-11-20 メルク シヤープ エンド ドーム リミテツド 肥満を治療するためのｎｋ−１受容体拮抗薬およびｓｓｒｉの使用
IT1291320B1 (it) 1997-05-08 1999-01-07 Borregaard Italia Spa Procedimento per la preparazione di composti aromatici contenenti un sistema eterociclico
ES2155995T3 (es) * 1997-06-10 2001-06-01 Synthon Bv Compuestos de 4-fenilpiperidina.
WO1999017803A1 (en) 1997-10-03 1999-04-15 Cary Medical Corporation Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
DE69919142T2 (de) 1998-03-17 2005-01-20 Pfizer Products Inc., Groton Bicyclo [2.2.1] heptane und verwandte verbindungen
US20030187269A1 (en) * 1998-04-17 2003-10-02 Curzons Alan David Novel process
GB9817195D0 (en) * 1998-08-07 1998-10-07 Smithkline Beecham Plc Novel process
US6376531B1 (en) * 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
WO2000044376A1 (en) 1999-01-28 2000-08-03 Bristol-Myers Squibb Company Antidepressant heterocyclic compounds
US20030055070A1 (en) 1999-07-01 2003-03-20 Wilma Harrison Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
GB9916187D0 (en) 1999-07-09 1999-09-08 Smithkline Beecham Plc Novel process
IL137937A0 (en) 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
EP1104760B1 (en) * 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
EP1134290A3 (en) * 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US20040229911A1 (en) 2000-05-17 2004-11-18 Pfizer Inc New pharmaceutical combinations for NOS inhibitors
DOP2001000154A (es) 2000-05-25 2002-05-15 Pfizer Prod Inc Combinación de secretagogos de hormona del crecimiento y antidepresivos
EP1181933A3 (en) 2000-06-29 2002-04-10 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating or increasing appetite
US6369051B1 (en) 2000-07-06 2002-04-09 American Home Products Corporation Combinations of SSRI and estrogenic agents
US20020077323A1 (en) 2000-07-12 2002-06-20 Mclean Stafford Use of delta opioid receptor ligands and serotonin reuptake inhibitors in the treatment of chemical dependencies
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US6436938B1 (en) * 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
WO2002085871A2 (en) 2001-04-04 2002-10-31 Wyeth Serotonergic agents with long-acting in vivo effects
US6656951B2 (en) 2001-04-24 2003-12-02 Wyeth 8-aza-bicyclo[3.2.1]octan-3-ol derivatives of 2,3-dihydro-1,4-benzodioxan as 5-HT1A antagonists
WO2002088145A1 (en) 2001-04-26 2002-11-07 Wyeth AZABICYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZACYCLOPENTA[a]NAPHTHALENE AS 5-HT1A ANTAGONISTS
US6861427B2 (en) 2001-04-26 2005-03-01 Wyeth Azabicyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline as 5-HT1A antagonists
US6821981B2 (en) 2001-04-26 2004-11-23 Wyeth Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]-quinoline as 5-HT1A antagonists
US6815448B2 (en) 2001-05-07 2004-11-09 Wyeth Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
EP1425017A1 (en) 2001-09-13 2004-06-09 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
EP1451156A4 (en) 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOCHINOLINVERBINDUNGEN
US20050014848A1 (en) 2002-01-23 2005-01-20 Pfizer Inc. Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
WO2003063781A2 (en) 2002-01-29 2003-08-07 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
DE60332816D1 (de) 2002-03-13 2010-07-15 Schering Corp Nk1-antagonisten
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
US20040224943A1 (en) 2003-02-19 2004-11-11 Leventer Steven M. Method of lowering body temperature with (R) - 2,3-benzodiazepines
CA2529083A1 (en) 2003-06-27 2005-01-06 Pfizer Products Inc. Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors
US20050070577A1 (en) 2003-07-03 2005-03-31 Pfizer Inc. Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
EP1644335A4 (en) 2003-07-11 2008-06-04 Bristol Myers Squibb Co TETRAHYDROQUINOLINE DERIVATIVES COMPRISING MODULATORS OF CANNABINOID RECEPTORS
US20050080084A1 (en) 2003-07-11 2005-04-14 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
WO2005018569A2 (en) 2003-08-22 2005-03-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin modulating agent for the treatment of neoplasia
EP1670460B1 (en) 2003-10-10 2014-11-26 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
PT1697370E (pt) 2003-12-19 2007-05-31 Bristol Myers Squibb Co Heterociclos azabicíclicos como moduladores do receptor de canabinóides
WO2005107716A1 (en) 2004-03-25 2005-11-17 Cadila Healthcare Limited Controlled release paroxetine-containing tablets based on a core and a coating
FR2869033B1 (fr) 2004-04-20 2006-06-02 Rhodia Chimie Sa Procede de preparation de methylenedioxybenzene
US20050266082A1 (en) 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
KR100920856B1 (ko) 2004-11-30 2009-10-09 (주)아모레퍼시픽 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
CN101146521A (zh) 2005-03-14 2008-03-19 太阳医药高级研究有限公司 提供包含纤维素和甲基丙烯酸衍生物包衣的口服药物输送系统
KR20070009934A (ko) 2005-07-16 2007-01-19 주식회사 씨티씨바이오 염산 파록세틴 서방정 및 이의 제조방법
US7863274B2 (en) 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
JP5301991B2 (ja) * 2005-07-29 2013-09-25 コンサート ファーマシューティカルズ インコーポレイテッド 新規なベンゾ［ｄ］［１，３］−ジオキソール誘導体
JP2009502961A (ja) * 2005-07-29 2009-01-29 コンサート ファーマシューティカルズ インコーポレイテッド 新規な医薬組成物
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
AU2006274565B2 (en) 2005-08-02 2012-05-17 Lupin Limited Novel controlled release compositions of selective serotonin reuptake inhibitors
CA2624179A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
EP1948646A2 (en) * 2005-11-14 2008-07-30 Auspex Pharmaceuticals Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
US20090291958A1 (en) 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
WO2008016677A2 (en) 2006-08-02 2008-02-07 Auspex Pharmaceuticals, Inc. Preparation and utility of deuterated amphetamines
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
AU2008299921B2 (en) 2007-09-13 2012-03-01 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
US20110257260A1 (en) * 2009-07-21 2011-10-20 Auspex Pharmaceuticals, Inc. 3,4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102924426A (zh) * 2012-11-14 2013-02-13 广西师范大学 胡椒乙胺缩5-氯水杨醛及其合成方法和应用
CN102942554A (zh) * 2012-11-14 2013-02-27 广西师范大学 胡椒乙胺缩水杨醛及其合成方法和应用
CN102942554B (zh) * 2012-11-14 2014-05-28 广西师范大学 胡椒乙胺缩水杨醛及其合成方法和应用
CN102924426B (zh) * 2012-11-14 2014-07-02 广西师范大学 胡椒乙胺缩5-氯水杨醛及其合成方法和应用
CN103980271A (zh) * 2014-05-30 2014-08-13 天津长森药业有限公司 黄藤素及其类似物的制备方法
CN104059030A (zh) * 2014-05-30 2014-09-24 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
CN110179792A (zh) * 2014-07-29 2019-08-30 深圳君圣泰生物技术有限公司 小檗碱盐、熊去氧胆酸盐、相关复方及其制备方法和应用
CN113735847A (zh) * 2021-09-10 2021-12-03 四川大学 一种盐酸小檗碱的合成制备方法

Also Published As

Publication number Publication date
EP2727915A1 (en) 2014-05-07
CA2698808A1 (en) 2009-03-19
US20090143432A1 (en) 2009-06-04
US9315483B2 (en) 2016-04-19
JP5647519B2 (ja) 2014-12-24
WO2009035652A1 (en) 2009-03-19
US8822498B2 (en) 2014-09-02
EP2200997A1 (en) 2010-06-30
EP2200997B9 (en) 2016-01-13
MX2010002692A (es) 2010-06-01
AU2008299921A1 (en) 2009-03-19
JP2010539166A (ja) 2010-12-16
AU2008299921B2 (en) 2012-03-01
EP2727915B1 (en) 2016-04-13
US20140336387A1 (en) 2014-11-13
AU2008299921A8 (en) 2010-04-08
EP2200997B1 (en) 2013-11-06

Similar Documents

Publication Publication Date Title
CN101855218A (zh) 氘化的儿茶酚和苯并[d][1,3]间二氧杂环戊烯及其衍生物的合成
JP5301991B2 (ja) 新規なベンゾ［ｄ］［１，３］−ジオキソール誘導体
US20080033011A1 (en) Novel benzo[d][1,3]-dioxol derivatives
ES2443127T3 (es) Nuevos derivados tricíclicos o sales de éstos farmacéuticamente aceptables, su procedimiento de fabricación y composiciones farmacéuticas que los contienen
US8912220B2 (en) Compounds and methods of use thereof
KR20080047375A (ko) 약제 화합물
CA2900308A1 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2023061095A1 (zh) 14-氯-β-榄香烯一氧化氮供体型衍生物及其制备和应用
US9475779B2 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
KR20080021134A (ko) 5-ｈｔ1ａ 수용체의 피페라진-피페리딘 길항제 및 효능제
EP2032561A2 (fr) Molecules duales contenant un derive peroxydique, leur synthese et leurs applications therapeutiques
EP1923387B1 (en) Acylguanidine derivative or salt thereof
EP1687312B1 (fr) Molecules duales contenant un derive peroxydique, leur synthese et leurs applications therapeutiques
KR20000062356A (ko) 5-ｈｔ 수용체 활성을 갖는 술폰아미드 화합물
JP2012211086A (ja) 関節リウマチの治療剤又は予防剤
WO2010028130A2 (en) Antidepressant compounds
EP3418270A1 (en) Novel biphenylsulfoximines as allosteric modulators of the dopamine d1 receptor
US20080221193A1 (en) 3-amino chromane derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20101006